Warfarin Dose and Genotypes in Myocardial Infarction Patients
Author Information
Author(s): Kari Bente Foss, Mohammad N Sharikabad, Marianne K Kringen, Sigrid Narum, Stine T Sjaatil, Per Wiik Johansen, Peter Kierulf, Ingebjørg Seljeflot, Harald Arnesen, Odd Brørs
Primary Institution: Ulleval University Hospital
Hypothesis
The study investigates the relationship between genotypes of CYP2C9 and VKORC1 and warfarin maintenance dose in patients with myocardial infarction.
Conclusion
CYP2C9 and VKORC1 genotype frequencies in myocardial infarction patients appear similar to other patient groups and have similar impact on warfarin maintenance dose.
Supporting Evidence
- Warfarin dosage requirement was significantly associated with CYP2C9 and VKORC1 genotypes.
- The VKORC1 genotype contributed 24.5% to the interindividual variation in warfarin dosage.
- The combined CYP2C9 genotypes were responsible for 7.2% of the dose variation.
Takeaway
Doctors can use genetic information to help decide how much warfarin medicine a patient needs after a heart attack.
Methodology
Genotyping was performed in 212 myocardial infarction patients using robotic isolation of DNA from blood samples.
Limitations
The study may be underpowered to detect differences in bleeding risk due to the small sample size of certain genotypes.
Participant Demographics
The study included 212 Caucasian patients with myocardial infarction.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website